TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2861315
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle for injection)
Study: 30404626
Drug: Dasatinib (SRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (SRC inhibitor)
Study: 24811331
Drug: Acetazolamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (2 × 250 mg/d)
Study: 20095796
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus paclitaxel (L + P)
Study: 12041767
Drug: Imipenem/cilastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (2 or 4 g/day)
Study: 24126967
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment comparator (MTC)
Study: 21130362
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (3 weeks duration)
Study: 9648697
Drug: Bla g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bla g 1 (cockroach allergen)
Study: 9648697
Drug: Bla g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bla g 2 (cockroach allergen)
Study: 31564452
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about vaccines recommended for HCWs
Study: 31564452
Drug: Knowledge about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge about hepatitis B and influenza vaccines
Study: 31564452
Drug: Prior receipt
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior receipt of all recommended vaccines
Study: 18324410
Drug: Glycerol and
Normalized name: Glycerol and honey only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol and icthammol (G&I) ribbon gauze
Study: 18324410
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic and steroid drops
Study: 11821506
Drug: Daily hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hemodialysis
Study: 1703746
Drug: Ampicillin-chloramphenicol combination
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin-chloramphenicol combination
Study: 23155345
Drug: Activated carbon
Normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated carbon nanoparticles suspension (ACNS), 1 mL subserosal injection in a 4-quadrant region around the mass.
Study: 23155345
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (MB), 2 mL injected into the isolated, stretched and fixed vessel after specimen removal.
Study: 16483177
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg ganirelix sc daily for 7 days
Study: 16483177
Drug: 0.250 mg
Normalized name: DIGOXIN 0.250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.250 mg ganirelix sc daily for 7 days
Study: 16483177
Drug: 0.500 mg
Normalized name: DOFETILIDE 0.500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.500 mg ganirelix sc daily for 7 days
Study: 10601934
Drug: Daily nonstress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nonstress test
Study: 10601934
Drug: Daily biophysical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily biophysical profile
Study: 8848515
Drug: Mecamylamine (nicotinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (nicotinic antagonist)
Study: 2286929
Drug: Selective elimination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective elimination of oral flora
Study: 31284490
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day anthocyanins (Group A)
Study: 31284490
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg lutein and 2 mg zeaxanthin per day (Group X)
Study: 31284490
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anthocyanins and xanthophylls (Group A+X)
Study: 24389883
Drug: Lateral decubitus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral decubitus, knee-chest position (group L, n = 100)
Study: 12052850
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TDN)
Study: 12052850
Drug: Nasal nicotine
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal nicotine spray (NNS)
Study: 10385777
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg aspirin daily (group A1)
Study: 10385777
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg aspirin on alternate days (group A2)
Study: 2370089
Drug: Product of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product of protein/creatinine ratio and estimated daily urinary creatinine excretion
Study: 93179
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (control)
Study: 23999452
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin glargine titrated to a fasting glucose of ≤ 5.3 mmol/L (95 mg/dL)
Study: 16781788
Drug: Omacor (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor (1 g/day)
Study: 15347469
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus HRT
Study: 9754466
Drug: Dialysis solution
Normalized name: dialysis solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis solution containing 2.5% glucose
Study: 9754466
Drug: Dialysis solution
Normalized name: dialysis solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis solution containing 1.5% glucose
Study: 8311013
Drug: Chemotherapy (CT:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT: cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 day 1 every 28 days for 6 courses)
Study: 30336702
Drug: Preferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred treatment (either Prolonged exposure or Sertraline)
Study: 26701606
Drug: α-mangostin nanoparticles
Normalized name: mangostin
DrugBank: Mangostin (DB14371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-mangostin nanoparticles applied twice daily for 4 weeks
Study: 23294853
Drug: 2-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-weekly docetaxel (50 mg/m² on days 1 and 15 of a 4-week cycle)
Study: 23294853
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (75 mg/m² on day 1 of a 3-week cycle)
Study: 18451243
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel
Study: 21511218
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel loading dose (LD)
Study: 21511218
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg clopidogrel loading dose (LD)
Study: 21511218
Drug: Both 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 300 mg and 900 mg clopidogrel loading doses
Study: 16595223
Drug: Drospirenone 3
Normalized name: drospirenone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 3 mg and ethinyl estradiol 30 microg for 12 cycles
Study: 10834865
Drug: Potent SAARD
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent SAARD with a long lag time (intramuscular gold, if necessary replaced by D-penicillamine)
Study: 9113250
Drug: 100-proof vodka
Normalized name: Clear Proof Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-proof vodka (1.5 ml/kg) in orange juice
Study: 8458059
Drug: 37.5 mg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg/hr cimetidine
Study: 8458059
Drug: 50 mg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/hr cimetidine
Study: 16049637
Drug: Rivastigmine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (mean dose 8.6 +/- 1.3 mg) for 12 months
Study: 16049637
Drug: Rivastigmine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (mean dose 10.5-12 mg) for 12 months
Study: 1457622
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg denbufylline BID
Study: 6326784
Drug: Intravenous prenalterol
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prenalterol (5 mg)
Study: 6326784
Drug: Sustained oral
Normalized name: Sustain Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained oral prenalterol (100 mg twice a day)
Study: 6326784
Drug: Placebo (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (during oral crossover study)
Study: 30983953
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (HAL-BWSTT and CPT)
Study: 26266401
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IPL + NIR + fractional Er:YAG laser)
Study: 26266401
Drug: IPL monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL monotherapy
Study: 17468667
Drug: Structured Treatment
Normalized name: Lipid,structured (From Sunflower Oil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Treatment Interruption (STI) arm
Study: 15978307
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 75 mg
Study: 15978307
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 50 mg vs 25 mg
Study: 15978307
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 75 mg vs 25 mg
Study: 6277020
Drug: Guar-containing biscuit;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar-containing biscuit; specific dosage and duration not mentioned.
Study: 31132118
Drug: Kisspeptin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kisspeptin administration
Study: 20701514
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg with FSH
Study: 20701514
Drug: Letrozole 5
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 5 mg daily with FSH
Study: 20843911
Drug: Duloxetine 60‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60‐120 mg/day
Study: 17414743
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 75‐225 mg/day
Study: 16288616
Drug: Capsaicin ointment
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin ointment
Study: 10188750
Drug: Bench press-load
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bench press-load (BP-L)
Study: 7797058
Drug: New anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: New anti-inflammatory agents (methotrexate, hydroxychloroquine, auronifin, sulfonylureas)
Study: 30782354
Drug: Self-reported medication
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported medication nonadherence measure
Study: 16030053
Drug: Cinacalcet (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (initiated at 30 mg, escalated to a maximum of 180 mg once daily)
Study: 16030053
Drug: Cinacalcet (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30 mg to 180 mg once daily)
Study: 11799484
Drug: TAC, prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC, prednisone, and MMF therapy (group T)
Study: 11799484
Drug: TAC and
Normalized name: Nystatin and Triamcinolone Acetonide Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC and prednisone therapy (group D)
Study: 6181324
Drug: BHT-933 5
Normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHT-933 5 mg
Study: 31755968
Drug: Intravitreal ziv-aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ziv-aflibercept 1.25 mg
Study: 31755968
Drug: Intravitreal ziv-aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ziv-aflibercept 2.5 mg
Study: 27544361
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin (100mg)
Study: 27544361
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline perfusion
Study: 27544361
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin (100mg) and IV saline
Study: 27544361
Drug: Rectal glycerin
Normalized name: glycerin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal glycerin (control)
Study: 19223675
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (3x500 mg tablets per day for 12 days)
Study: 15649728
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU dalteparin injections once daily for 3 months
Study: 15649728
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections once daily for 3 months
Study: 10436143
Drug: Argatroban infusion
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban infusion therapy (continuous intravenous infusion for 60 minutes, repeated daily for 2 weeks)
Study: 10436143
Drug: Argatroban infusion
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban infusion therapy
Study: 7776528
Drug: Ketamine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.1 mg.kg‐1 + bupivacaine 5 ml
Study: 7776528
Drug: Ketamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.3 mg.kg‐1 + bupivacaine 5 ml
Study: 7776528
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg.kg‐1 + bupivacaine 5 ml
Study: 7776528
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 5 ml only
Study: 14688490
Drug: Multiple-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-drug therapy
Study: 31489467
Drug: Dried beancurd
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried beancurd (100 g/day)
Study: 31489467
Drug: Rice cake
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice cake (control group, 100 g/day)
Study: 30417894
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of pressed ceramic
Study: 30417894
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of pressed ceramic
Study: 30417894
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of pressed ceramic
Study: 30417894
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of pressed ceramic (aged)
Study: 30417894
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of pressed ceramic (aged)
Study: 30417894
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of pressed ceramic (aged)
Study: 26770983
Drug: Acarbose (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (150 mg/day)
Study: 22314263
Drug: Dextromethorphan/quinidine (DMQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan/quinidine (DMQ) 45/30 mg
Study: 22314263
Drug: Dextromethorphan/quinidine (DMQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan/quinidine (DMQ) 30/30 mg
Study: 7742436
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Oka/Merck varicella vaccine
Study: 7742436
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of Oka/Merck varicella vaccine
Study: 2139442
Drug: Aspirin (324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (324 mg/day)
Study: 29514801
Drug: Intramuscular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular glucocorticoid injection (40 mg triamcinolone acetate)
Study: 26509817
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg IV methylprednisolone (neonate trial)
Study: 26509817
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg IV methylprednisolone after anesthesia induction (ventricular septal defect trial)
Study: 26509817
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg methylprednisolone in the cardiopulmonary bypass prime solution (ventricular septal defect trial)
Study: 26509817
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg IV methylprednisolone (ventricular septal defect trial)
Study: 24447620
Drug: Olesoxime (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olesoxime (330 mg daily)
Study: 19965659
Drug: MEL200 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL200 (200 mg/m²)
Study: 19965659
Drug: MEL100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL100 (100 mg/m²)
Study: 18206857
Drug: 18 mg/day
Normalized name: lenvatinib mesylate 18 mg/day (10 mg x 1 and 4 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg/day prolonged-release methylphenidate
Study: 18206857
Drug: 36 mg/day
Normalized name: scopolamine 0.3336 MG/Day 72 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg/day prolonged-release methylphenidate
Study: 18206857
Drug: 72 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 mg/day prolonged-release methylphenidate
Study: 16816797
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Study: 16816797
Drug: Conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotic (perphenazine)
Study: 10845350
Drug: Preparation group
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation group (videotape shown the evening before surgery)
Study: 8805113
Drug: 10% peppermint
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% peppermint oil in ethanol solution
Study: 8805113
Drug: Placebo (90%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (90% ethanol solution with traces of peppermint oil)
Study: 1610539
Drug: Cholestyramine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (24 g daily)
Study: 1610539
Drug: Lovastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (80 mg daily)
Study: 6428899
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of hydroxy‐ethyl‐starch cryopreserved blood with free haemoglobin
Study: 20447535
Drug: Low-level increases
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level increases in cTnI (0.04 microg/l to <0.1 microg/l)
Study: 16225575
Drug: hCG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG treatment
Study: 12405574
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (group A)
Study: 12405574
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (group B)
Study: 31977882
Drug: Supervised early
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised early exercise program in combination with standard treatment
Study: 26179181
Drug: Citicoline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (250 or 500 mg)
Study: 25376719
Drug: Active hexose
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active hexose correlated compound (1.0 g/d for 4 weeks)
Study: 23778476
Drug: 0.3% gatifloxacin/1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% gatifloxacin/1% prednisolone acetate fixed combination eye drops
Study: 16717081
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Hb decrease of >3 g/dL
Study: 16717081
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Hb decrease of 2.0-3.0 g/dL
Study: 15259286
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous combined E2 1 mg and NETA 0.25 mg
Study: 15259286
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous combined E2 1 mg and NETA 0.5 mg
Study: 3901389
Drug: Org OD14
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org OD14 (2.5 mg daily for 12 weeks)
Study: 31675674
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training combined with nutritional supplement (RTS)
Study: 22036605
Drug: Intranasal hypocretin-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal hypocretin-1 (orexin A) (435 nmol)
Study: 19644228
Drug: Fast-titration group
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-titration group (4 mg/24 h starting dose, increasing by 4 mg/24 h per week to a maximum of 24 mg/24 h)